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Background: Established risk models for the prediction of cardiovascular disease (CVD) include blood pressure,
smoking and cholesterol parameters. The use of total cholesterol for CVD risk prediction has been questioned,
particularly for primary prevention. We evaluated whether glucose could be used instead of total cholesterol for
prediction of fatal CVD using data with long follow-up.
Methods: We followed-up 6,095 men and women aged ≥16 years who participated 1977–79 in a community
based health study and were anonymously linked with the Swiss National Cohort until the end of 2008. During
follow-up, 727 participants died of CVD. Based on the ESC SCORE methodology (Weibull regression), we used age,
sex, blood pressure, smoking, and fasting glucose or total cholesterol. The mean Brier score (BS), area under the
receiver-operating characteristic curve (AUC) and integrated discrimination improvement (IDI) were used for model
comparison. We validated our models internally using cross-validation and externally using another data set.
Results: In our models, the p-value of total cholesterol was 0.046, that of glucose was p < 0.001. The model with
glucose had a slightly better predictive capacity (BS: 2216x10-5 vs. 2232x10-5; AUC: 0.9181 vs. 0.9169, IDI: 0.009 with
p-value 0.026) and could well discriminate the overall risk of persons with high and low concentrations. The
external validation confirmed these findings.
Conclusions: Our study suggests that instead of total cholesterol glucose can be used in models predicting overall
CVD mortality risk.
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Estimation of individual risk of cardiovascular disease
(CVD) is traditionally based on age, sex, smoking status,
blood pressure and cholesterol parameters. Based on these
variables, the SCORE (Systematic COronary Risk Evalu-
ation) risk model predicts fatal CVD events [1]. However,
in our general population sample from Switzerland
(National Research Project 1A, NRP 1A) with a follow-
up time of 32 years [2], total cholesterol performed only
poorly in this CVD model. Moreover, lowering choles-
terol for primary prevention of CVD has recently been
challenged [3]. In contrast, there is increasing evidence
for glucose parameters being independent CVD risk
factors [4]. This variable was also available in NRP 1A, and
we tested the use glucose instead of total cholesterol for* Correspondence: david.faeh@uzh.ch
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reproduction in any medium, provided the orrisk prediction with the SCORE approach which has a CVD
risk chart as central visual element. This chart allows the in-
clusion of not more than five variables [1]. We validated our
results internally and externally [5]. As in other developed
countries, in Switzerland, CVD mortality has substantially
decreased over the past three decades, resulting in inter-
nationally very low figures [6,7]. Despite this, Switzerland
has fairly high total cholesterol concentrations compared to
other countries [8]. The prevalence of major CVD risk
factors remained relatively stable or only slightly declined
over the past three decades [6,9].Methods
Study population
Risk factor data stems from men and women aged ≥16
years who participated in the National Research Program
1A (NRP 1A), a community health promotion initiative fo-
cused on cardiovascular disease prevention and conductedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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follow-up by anonymously linking the NRP1A data with
the Swiss National Cohort (SNC). The SNC encompasses
all residents of Switzerland enumerated in the national
1990 or 2000 censuses as well as data from death and emi-
gration registries [10].
Overall 8,008 out of 8,631 original participants (92.8%)
could be linked, loss to follow-up 1980–2000 was 5.8%.
Median follow-up was 30.8 years (IQR: 22.4 – 31.1 years)
and the 95th centile of follow-up was 31.2 years. In total
1,234 men and 1,193 women died, of whom 471 and 466
from CVD [11]. Since there was no census at the end of
the study, loss to follow-up after the 2000 census could
not be determined, i.e. all 5,019 individuals linked to the
2000 census but not to a succeeding death or emigration
record were assumed to have survived. Between 1990 and
2000, no satisfactory link to a mortality record, emigration
record or 2000 census record could be found for 6.9% of
the persons registered in the 1990 census [10]. A similar
proportion of all registered deaths between the 2000 cen-
sus and the end of 2008 (6.2%) could not be linked to a
2000 census record [10]. Similar figures can be expected
for the period 2000–2010.
Measurements and outcomes
Blood sampling, glucose and cholesterol measurements
were described in detail [2]. Briefly, 5ml of blood were
sampled and immediately thereafter centrifugated for
10 minutes at 3000 rpm. The plasma was then sent at
4°C to a laboratory in Bern or Geneva where they were
analyzed with a Greiner Electronic Selective Analyzer
(GSA) II or a ABA 100 (Abbott laboratories). No other
lipid parameters were measured. The results of the
internal and external quality control were excellent (day-
to-day variability based on the lowest age-specific variance
was 1.78% and 2.7%) [2]. Some samples were not taken in
fasting state. However, exact times of sampling and of last
meal were reported. Persons who had a meal within
two hours before sampling were excluded (n = 1901).
Smoking status was assessed with a self-administered
questionnaire. We defined smoking as smoking > =1
cigarette/d. Non-smokers include former and never
smokers. Systolic blood pressure was measured with a
sphygmomanometer in a sitting position; we took the
mean out of two measurements. Persons with values ≥
160/95 mmHg were referred to their GP [2]. Fatal CVD
events were defined according to ICD (International
Classification of Diseases) revisions 8 (ICD-8: 390–458,
until 1994) and 10 (ICD-10: I00-I99).
Statistical analyses
After exclusion of persons with missing covariate infor-
mation, 2,768 men and 3,327 women remained for ana-
lysis, of whom 354 and 373 died of CVD. Risk modelswere calculated using Weibull proportional hazards
regression as described [1]. We calculated the 10-year risk
of death from CVD. Note that the complete follow-up
time is used for model fitting, thus incorporating all
possible information from the data, and the desired pre-
diction time of 10 years is chosen afterwards. This pre-
diction time can be chosen arbitrarily once the model is
fitted. In separate sensitivity analyses (Weibull) we also
calculated the 20- and 30-year risk (Additional file 1:
Figures A3 and A4). We also combined glucose and
cholesterol together with the other CVD-risk variables
in a single model with two strata for sex (Additional
file 1: Table A1) and, in an additional model, included
the variable "known diabetes".
In order to compare the predictive abilities of the
cholesterol and the glucose model, we calculated the
cross-validated (leave-one-out) mean Brier score [12],
the area under the receiver-operating characteristic curve
(AUC) and the integrated discrimination improvement
(IDI). A permutation test [13] was used for the compari-
son of Brier scores from different models, and a Wald test
was applied in the case of the IDI [14]. The Brier score
measures the mean squared difference between the risk
score and the actual outcome. The lower this deviation,
the better the respective risk prediction model. We chose
the Brier score because it covers both calibration and
sharpness of a prediction model. In contrast, the AUC is
mainly a measure for the risk score’s ability to classify cor-
rectly. The IDI is a measure of improvement in model
performance and represents the difference in discrimin-
ation slopes in the two competing models.
We additionally used the US-based NHANES (National
Health and Nutrition Examination Survey) III data set
to validate our proposed risk score externally. From this
data set, only Non-Hispanic white participants who
provided a fasting blood sample (4,255 persons, 738
CVD deaths) were used for comparison [15]. The 10-year
risk of CVD death was calculated for each individual,
using the estimated coefficients from our Weibull models.
From these risks, the mean Brier score, AUC and IDI
were calculated.
Analyses were performed with STATA 11 (Stata Corp,
Texas, USA, 2009) and R (R Foundation for Statistics
Computing, version 2.14.1).
Results
The mean age at baseline was 42.4 years (men) and
44.1 years (women). 50.3% of men and 27.7% of women
were current smokers. In men and women, respectively,
mean systolic blood pressure was 130.2 mmHg and
125.4 mmHg, mean fasting glucose concentration was
5.4 and 5.2 mmol/L. Mean total cholesterol concentra-
tion was 6.0 mmol/L in both sexes. Of the 160 persons
who reported having diabetes, 98 were treated only
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required injections.
As shown in Table 1 the mean Brier score of the model
with glucose (2216x10-5) and cholesterol (2232x10-5) were
similar, and no statistically significant difference could be
found (p-value 0.287). Since strong explanatory variables
(age, sex, smoking, blood pressure) other than glucose or
cholesterol remained the same in the two models, the dif-
ference between the Brier scores was expected to be small,
stressing the comparability of the results from both risk
prediction models. The slightly higher AUC of the model
with glucose (0.9181 vs. 0.9169) and the joint model
(Additional file 1: Table A1) suggests some advantage
for glucose. This finding is confirmed by the statistically
significant positive value of the IDI (0.009; p-value: 0.026).
In separate analyses including all study participants with
cholesterol values (i.e. also persons with non-fasting glu-
cose values, n = 7,991), total cholesterol was statistically
not significant (p = 0.089).
As shown in Figure 1, glucose can well discriminate
persons at high and low CVD risk at virtually all ages
and blood pressure levels, irrespective of smoking status.
Particularly at older ages, there were strong synergistic
effects of the combination of glucose with smoking and
in particular with blood pressure. Sensitivity analyses
showed that glucose remained significant (p < 0.001) in a
joint model with cholesterol while cholesterol was not
significant (p = 0.073). Thus, cholesterol could not con-
tribute to the explanation of the association between riskTable 1 Estimated parameters and coefficients of the two mo
Model with glucose
Estimate (95% CI) P-valu
α men −47.7 (−50.7; -44.4) <0.00
p men 9.9 (9.2; 10.6) <0.00
α women −58.8 (−62.7; -54.9) <0.00
p women 12.4 (11.5; 13.2) <0.00
Current smoking 0.37 (0.20; 0.54) <0.00
Systolic blood pressure (mmHg) 0.01 (0.01; 0.02) <0.00
Glucose (mmol/l) 0.10 (0.06; 0.14) <0.00
Cholesterol (mmol/l)
Model comparison
Brier score (mean, cross-validated) 2216 x 10-5
AUC (cross-validated) 0.9181
IDI (glucose vs. cholesterol)
Model comparison, external validation*
Brier score (mean) 7662 x 10-5
AUC 0.8766
IDI (glucose vs. cholesterol)
*with data from the third National Health and Nutrition Examination Survey (NHAN
AUC area under the receiver-operating characteristic curve; IDI integrated discriminafactors and mortality when glucose was included in the
same model (Additional file 1: Table A1). Stratifying risk
estimation based on blood glucose for persons with high
and low cholesterol concentration did also not result in
a substantial improvement in risk estimation (Additional
file 1: Figure A1). In the common model with cholesterol,
further adjustment for self-reported diabetes ("known
diabetes") had no significant impact on estimates (not
shown).
The external validation using the NHANES III data,
confirmed the overall pattern (Table 1): The results with
glucose and cholesterol are comparable and also suggest
slightly better predictive performance of the model
with glucose (Brier score: 7662x10-5 vs. 7744x10-5 with
p-value 0.245; AUC: 0.8766 vs. 0.8737; IDI:0.029 with
p-value < 0.001).
Discussion
Our models based on data from Switzerland suggest that
instead of cholesterol, blood glucose could be used for
prediction of fatal CVD. In fact, glucose performed simi-
larly in our CVD risk prediction model. In contrast to
cholesterol, the coefficient of glucose remained statistically
significant in a joint model including both glucose and
cholesterol. Traditional CVD risk models do not consider
glucose. The PROCAM and the Framingham models in-
clude information about diabetes (yes/no) but this does
not sufficiently map the potential impact of blood glucose
on CVD [16,17]. As shown by us and others, there is adels
Glucose vs. cholesterol Model with cholesterol
e Estimate (P-value) Estimate (95% CI) P-value
1 −47.5 (−50.7; -44.4) <0.001
1 9.9 (9.2; 10.6) <0.001
1 −58.5 (−62.4; -54.6) <0.001
1 12.5 (11.7; 13.1) <0.001
1 0.34 (0.17; 0.51) <0.001
1 0.01 (0.01; 0.02) <0.001
1
0.10 (0.00; 0.20) 0.046
(0.287) 2232 x 10-5
0.9169
0.009 (0.026)





Figure 1 Chart for absolute 10-year risk of fatal cardiovascular disease based on the model using blood glucose instead of cholesterol,
6,095 participants of the NRP1A study conducted in Switzerland in 1977–79, ages >16 years at baseline. NRP1A: National Research
Program 1A, entire population with full follow-up is considered. Each risk percentage is calculated using a combination of given risk factor values.
E.g., a man aged 65, smoker, with a systolic blood pressure of 180 and a fasting blood glucose of 6 mmol/L has an absolute risk of fatal CVD
of 15%.
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tality risk increases at concentrations around ≥6 mmol/L
[4,18,19]. This threshold may be even lower when other
CVD risk factors, e.g. high blood pressure or smoking are
present [20,21]. Such combinations are presented in our
chart. The advantage of using blood glucose in a continu-
ous instead of a dichotomized form is that the chart could
be used by physician to prevent or delay the onset of
diabetes in persons with prediabetic glucose concentrations
and reduce morbidity and premature death. It could
be used to motivate individuals to follow lifestyle
recommendations and to increase compliance. In fact,
glucose parameters can be improved with physical activity,weight management and healthy diet and thus open doors
for lifestyle recommendations and underline their signifi-
cance [22-24]. Prediabetes can also be effectively treated
with Metformin which can decrease the rate of conversion
from prediabetes to diabetes [22,25,26]. Approaching per-
sons early in the pathway to diabetes may be much more
effective than treating them when diabetes is established.
This is not possible when the risk associated with
increased glucose concentrations is only considered di-
chotomously (no diabetes / diabetes).
Using glucose may also have practical advantages, be-
cause it can easily and reliably be measured e.g., from
capillary blood or even from saliva [27]. The assessment
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sive and in case of cholesterol ratio requires two
measurements. Moreover, blood glucose is routinely
assessed in clinical practice or self-controlled by many
patients. This enables a straightforward and continuous
monitoring of CVD risk.
The impact of cholesterol as CVD risk factor in per-
sons with low CVD risk has been questioned recently
[3]. In our study, lag of time between measurement of
risk factors and death was up to 32 years. Since only
baseline information was available, we cannot determine
whether participants were treated with lipid lowering
medication or diabetes medication. In Switzerland,
cholesterol-lowering statin drugs are used since the end
of the 1980s. In 2002 and 2007 respectively, 5.0% and
7.4% of men and 3.4% and 4.9% of women reported daily
treatment of increased cholesterol levels [28]. Anti
diabetic drugs are used since 1960 in Switzerland
(Metformin). In 2007, 2.9% of men and 2.0% of
women reported being treated daily for diabetes [28].
Our study has several limitations. CVD risk factors
could only be assessed once (at baseline) and there is no
information about changes in exposures. The found as-
sociation with mortality can thus be assumed to be con-
servative, i.e. an underestimation of the “real” magnitude
of the effect. Previous sensitivity analyses showed, how-
ever, that point estimates for relative risks of CVD risk
factors only moderately differed if 10 or 15 years were
considered instead of the full follow-up time [29]. An
underestimation can also be expected from the fact that
we may have included non-fasting persons. In fact,
restricting to persons who did not eat four hours (instead
of two) before blood sampling resulted in higher risks in
virtually all strata (see Additional file 1: Figure A2).
Another limitation is the fact that the competing risk
of non-CVD mortality was not accounted for in our
models. Estimated baseline hazards are necessary for our
risk calculations and can be obtained by using Weibull
regression (as performed). Unfortunately, this estimation
is not possible with standard competing risks method-
ology. Some bias might be introduced by not considering
competing risks, however, this bias is generally supposed
to be small.
A part of the original study participants could not be
linked (7.2%), emigrated (2.7%) or was lost to follow-up
(3.8%, not considering the unknown figure for 2000–08).
However, even on the long run, this proportion remains
rather modest. In line with other health surveys, the
NRP 1A participants were most likely healthier than the
general population [30]. Our end-point was limited in
the sense that we were restricted to fatal CVD. CVD
mortality data from death certificates is reliable for
young and middle aged persons but may cause misclassi-
fication in elderly [31]. However, overall, in Switzerland,the validity (58-77%) and reliability (90-97%) of coding
of CVD deaths from death registry may be regarded as
acceptable [32]. The appearance of the traditional ESC
chart is predefined and we wish to adhere to it. There-
fore we could not display glucose AND cholesterol in
the same chart [33]. In our population, we found no
evidence for a substantial advantage of including chol-
esterol in addition to glucose (see Additional file 1:
Table A1, Figure A1).
Conclusion
Our results are a hint that established CVD risk prediction
models are worth being revisited. However, the perform-
ance of glucose vs. cholesterol needs to be validated with
populations from countries outside Europe and the USA.
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